Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 5, 2004, Pages 560-567

  Van Deun, Armand ^a   Hamid Salim, M A ^b   Kumar Das, A P ^b   Bastian, I ^c   Portaels, F ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Damien Foundation Bangladesh   (Bangladesh)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Control; Multi drug resistance; Treatment; Tuberculosis

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTHRITIS; ARTICLE; BACTERIAL STRAIN; BANGLADESH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ERUPTION; DRUG FATALITY; FEMALE; HUMAN; JAUNDICE; LIVER DYSFUNCTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIDRUG RESISTANCE; NAUSEA; NEURITIS; NEUROTOXICITY; PRIORITY JOURNAL; RELAPSE; RESPIRATORY FAILURE; SHORT COURSE THERAPY; SIDE EFFECT; STANDARDIZATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; VOMITING;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BANGLADESH; CLINICAL PROTOCOLS; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 2442653062     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. World Health Organization. WHO Tuberculosis Programme: framework for effective tuberculosis control. Geneva, Switzerland: WHO, 1994.
2. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: WHO, 1997.
3. Kochi A. Tuberculosis control - is DOTS the health breakthrough of the 1990s'? World Health Forum 1997; 18: 225-247.
4. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
5. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
6. Farmer P, Kim J Y. Community based approaches to the control of multidrug resistant tuberculosis: introducing 'DOTS-plus'. Brit Med J 1998; 317: 671-674.
7. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
8. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
9. Park M M, Davis A L, Schluger N W, Cohen H, Rom W N. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.
10. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-884.
11. Farmer P, Furin J, Shin S. Managing multidrug-resistant tuberculosis. J Respir Dis 2000; 21: 53-56.
12. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
13. Tahaoglu K, Torün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
14. Arnadottir T, Binkin N, Cegielski P, et al. Guidelines for establishing DOTS-plus pilot projects for the management of multidrug resistant tuberculosis (MDR-TB). WHO/CDS/TB/2000.279. Geneva, Switzerland: WHO, 2000
15. Suárez, P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
16. Van Deun A, Hamid Salim A, Daru P, et al. Drug resistance monitoring-combined rates may be the best indicator of programme performance. Int J Tuberc Lung Dis 2004; 8: 23-30.
17. Crofton J, Chaulet P, Maher D, et al. Guidelines for the management of drug resistant tuberculosis. Geneva, Switzerland: World Health Organization, 1997.
18. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
19. Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999; 58: 633-661.
20. Abate G, Hoffner S E, Thomsen V Ø, Miörner H. Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG. Eur J Clin Microbiol Infect Dis 2001; 20: 329-333.
21. Victor T C, Warren R, Butt J L, et al. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. Med Microbiol 1997; 46: 847-857.
22. Jagannath C, Reddy V M, Kailasam S, O'Sullivan J F, Gangadharam P R. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083-1086.
23. Bulatovic V M, Wengenack N L, Uhl J R, et al. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrobiol Agents Chemother 2002; 46: 2765-2771.
24. Smithwick R W, Stratigos C B, David H L. Use of cetylpyridinium chloride and sodium chloride for the decontamination of sputum specimens that are transported to the laboratory for the isolation of Mycobacterium tuberculosis. J Clin Microbiol 1975; 1: 411-413.
25. Petroff S A. A new and rapid method for the isolation and cultivation of tubercle bacilli directly from sputum and feces. J Exp Med 1915; 21: 38-42.
26. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
27. Heifets, L. Conventional methods for antimicrobial susceptibility testing of Mycobacterium tuberculosis. In: Bastian I, Portaels F, eds. Multidrug-resistant tuberculosis. Dordrecht, The Netherlands: Kluwer Academic Publications, 2000: pp 133-143.
28. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
29. Mühlberger F, Nturanye F, Nsabimana J, Portaels F. Ofloxacin-cycloserine-prothionamide-INH combination against treatment refractory lung tuberculosis. Pneumologie 1995; 49: 72-76.
30. Becerra M C, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114.
31. Grimaldo E R, Tupasi T E, Rivera A B, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.